ArticleFrontiers in public health2024
Risk assessment of human-to-human transmission of severe fever with thrombocytopenia syndrome virus based on 10-year clustered analysis.
Article in Frontiers in public health, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed.
- Evaluation of new adjuvants in enhancing the immune response to a candidate of Severe Fever with Thrombocytopenia Syndrome Virus vaccine.bioRxiv : the preprint server for biology · 2026Article
- Effectiveness of lignans against severe fever with thrombocytopenia syndrome virus infection.Virologica Sinica · 2026Article
- Immune Cells at the Frontline of SFTSV Infection.Journal of microbiology and biotechnology · 2026Review
- One Health-based Joint Epidemiological Investigation of a Severe Fever with Thrombocytopenia Syndrome Case in the Republic of Korea, 2025.Public health weekly report · 2026Article
- Current status of severe fever with thrombocytopenia syndrome in China (Review).International journal of molecular medicine · 2025Review
- Epidemiological characteristics of severe fever with thrombocytopenia syndrome and the relationship with meteorological factors in Jiangsu Province, China.Frontiers in public health · 2025Article
- Clinical Value of Complement C3a, C5a, and sC5b-9 in Evaluating the Severity of Patients with Severe Fever with Thrombocytopenia Syndrome.Journal of inflammation research · 2025Article
- Defining the kinetics of severe fever with thrombocytopenia syndrome virus acquisition and dissemination in naturally-infectedFrontiers in cellular and infection microbiology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Severe fever with thrombocytopenia syndrome (SFTS) is an acute infectious disease, which was first reported in 2009 in China. Previous studies have rarely quantitatively assessed the transmission and fatal risk of SFTS clusters. Methods: Epidemiological information regarding SFTS clusters in Yantai city of Shandong province during 2013-2022 was obtained from the National Public Health Emergency Event Surveillance System (PHEESS) for Disease Control and Prevention information system. The secondary attack rate (SAR) and relative risk (RR) were used to assess the risk of human-to-human transmission of SFTS. Results: A total of 20 SFTS clusters involving 51 laboratory-confirmed patients were reported between 2013 and 2022 in Yantai city, Shandong province. Most of the clusters occurred from May to October, and the patients were mainly distributed in four counties. Contact with blood or other fluids [RR = 14.06, 95% confidence interval (CI) = 3.29-70.65, Conclusion: Our study may provide direct guidance on health education and behavioral interventions for the accompanying relatives and personnel of SFTS patients, both during their hospital stay and upon returning home after discharge.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.